Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Inclusion Criteria:

- Subject must be ≥ 18 years of age. Life expectancy > 12 weeks.

- Subject must have cytologically or histologically confirmed advanced or metastatic
non-squamous NSCLC and are current or former smokers.

- Subject must have NSCLC that is not amenable to surgical resection or radiation with
curative intent at time of screening.

- Subject must have at least 1 unidimensional measurable NSCLC lesion on a CT scan as
defined by RECIST (version 1.1).

Exclusion Criteria:

- Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with
polyethoxylated castor oil (Cremophor).

- Subject has a known hypersensitivity to platinum compounds.

- Subject has peripheral neuropathy ≥ grade 2.

- Subject has squamous NSCLC, or an untreated known EGFR mutation of exon 19 deletion or
L858R mutation in exon 21, or a known ALK gene rearrangement.

- Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC.